A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Pharmacokinetic and Safety Study of PTl-125 in Healthy Volunteers
Latest Information Update: 11 May 2021
At a glance
- Drugs Simufilam (Primary)
- Indications Alzheimer's disease
- Focus First in man; Pharmacokinetics
- Sponsors Cassava Sciences; Pain Therapeutics
- 14 Dec 2017 According to a Pain Therapeutics media release, full results of this study were presented at the 10th Annual International Conference on Clinical Trials on Alzheimers Disease (CTAD) 2017.
- 24 Oct 2017 According to a Pain Therapeutics media release, this trial was supported with research grant award from the National Institute on Aging, part of the National Institutes of Health.
- 24 Oct 2017 According to a Pain Therapeutics media release, full results of this study will be presented at the 10th Annual International Conference on Clinical Trials on Alzheimers Disease (CTAD) 2017.